Despite pharmacological equivalence, generic vancomycin preparations exhibited inferior antimicrobial activity compared with the brand product in an infection model. According to WHO regulations ...
A recent study by a team from Chiba University has demonstrated a promising approach for fighting antibiotic resistance by identifying a compound, V-161, that inhibits a sodium-pumping enzyme critical ...
Purpose. The feasibility of using a limitedsampling algorithm for administration of vancomycin for treatment of vascular-access-related bacteremia in outpatient high flux hemodialysis was ...
Vancomycin (as HCl) 500mg/vial, 1g/vial; lyophilized pwd for IV infusion after reconstitution and dilution. The bactericidal action of vancomycin results primarily from inhibition of cell-wall ...
V-161, a novel compound targeting the Na+ -V-ATPase enzyme in vancomycin-resistant Enterococcus faecium (VRE), significantly ...
Highlights: New Research Collaboration with Monash University One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum therapeutic drug productsSecond project proposal will ...
Immuron Limited (IMRN), an Australian-based biopharmaceutical company, Wednesday, announced a new research collaboration with Monash ...
Immuron (IMRN) announced a new research collaboration agreement with Monash University. The major objective of this research collaboration is ...
They compared data from 80 health care clinics and compared it with the treatment of Intravenous Vancomycin. The results show that oral tablets of Linezolid (ZYVOX), provides better treatment and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback